Core Insights - Phio Pharmaceuticals Corp. announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762, leading to a significant increase in share price [1] - The company has a market cap of $9 million and experienced a trading volume of 5.82 million, significantly higher than the average of 412.49 thousand [1] Safety Data Update - The Safety Monitoring Committee reported no serious adverse events or dose-limiting toxicities across all five dose escalation cohorts [2] - The highest dose concentration achieved an pathological response rate of 85%, with complete tumor clearance in four out of six responders [2] Treatment Details - A total of 22 patients with cutaneous carcinomas completed treatment, receiving 4 intratumoral injections of PH-762 [3] - The drug was evaluated in five dose-escalating cohorts, with a 20-fold increase in drug concentration from the first to the fifth cohort [3] Next Steps - An FDA submission for guidance on next steps in clinical study design for PH-762 is targeted for the second quarter of 2026 [4] - The company is on track to have material available for non-human primate studies by March 2026, which is necessary for commencing human pivotal trials [5] Technical Analysis - Phio Pharmaceuticals is currently trading 12.5% below its 20-day simple moving average (SMA) and 17.3% below its 50-day SMA, indicating a bearish trend [6] - Over the past 12 months, shares have decreased by approximately 49.44%, positioning the stock closer to its 52-week lows [6] Price Action - Phio Pharma shares were up 51.11% at $1.36 at the time of publication [8] - Key resistance level is at $1.00, while key support is at 81 cents [8]

Core Insights - Proactive provides fast, accessible, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, mining, oil and gas, and emerging technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]